Strides Pharma FY26 Net Profit Up 40% YoY

Strides Pharma reported FY26 revenue of INR48.6B, up 6.4% YoY, with EBITDA growing 15% to INR9.25B and net profit surging 40% to INR5.75B.
Ex-US markets drove growth with 21% revenue increase, now contributing 46% of total revenue, while US business faced headwinds from weak flu season.
Company maintained strong profitability with EBITDA margins expanding 140bps to 19% and operational PAT growing 50% to INR5.18B, while reducing net debt-to-EBITDA to 1.55x.
Management provided FY28 US revenue aspiration of $375-400M and long-term margin targets of 20%+ EBITDA, with dividend of INR5 per share recommended.